A phase IIb randomized, sham-controlled study of GEM-103 to limit geographic atrophy
Latest Information Update: 18 Jan 2023
At a glance
- Drugs Recombinant complement factor H Gemini Therapeutics (Primary)
- Indications Dry age-related macular degeneration
- Focus Therapeutic Use
- 29 Dec 2022 According to a Disc Medicine media release, Gemini Therapeutics has merged with the Disc Medicine and the combined company is named as Disc Medicine.
- 15 Nov 2021 According to a Gemini Therapeutics media release, this study is expected to begin in the first quarter of 2022.
- 05 Oct 2021 According to a Gemini Therapeutics media release, the company expect to initiate this study in early-2022.